The Lynx Group

August 2014, Vol 5, No 6

The FDA approved idelalisib (Zydelig; Gilead Sciences) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) to be used in combination with rituximab (Rituxan).
Read Article

The FDA approved belinostat (Beleodaq; Spectrum Pharmaceuticals) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL).
Read Article

Value Propositions from the August 2014 issue of Value-Based Cancer Care.
Read Article

The 340B Drug Pricing Program was a result of Public Law 102-585, the Veterans Health Care Act of 1992, which was codified as Section 340B of the Public Health Service Act.
Read Article

Los Angeles, CA—Patient comfort and emotional support are part of the quality components in value-based cancer care.
Read Article

The cancer drug pipeline continues to boast many new therapies, reinforcing the recent trends of new and improved monoclonal antibodies and other classes of targeted therapies for different types of tumors.
Read Article

According to the 2013 Annual Report on Progress Against Cancer published in 2014 by the American Society of Clinical Oncology (ASCO), cancer death rates have declined by 21% among men and by 12% among women since the 1990s, and more than 13 million cancer survivors are alive in the United States today.
Read Article

Nonadherence to medication has been associated with financial burden; however, little is known about the association between the discussion of cancer treatments between patients and oncologists regarding out-of-pocket cost and medication adherence.
Read Article

Lung cancer is one of the most frequently diagnosed cancers, as well as the leading cause of cancer-related mortality in the United States.
Read Article

Page 4 of 4

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: